Related Experiment Video
Updated: May 28, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Chronic schizophrenia-a psychopharmacological aproach
1Professor of Psychiatry, Vanderbilt University, 242 Medical Arts Bldg., 1211 21st Ave. S., Nashville, TN 37212, USA.
Indian Journal of Psychiatry
|October 4, 2011
Summary
This study explores schizophrenia subtypes, suggesting biochemical differences, particularly dopamine activity, influence treatment response. New drug targets like propranolol and cholecystokinin may benefit specific patient groups.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia classification systems are evolving.
- Biochemical underpinnings of schizophrenia subtypes remain incompletely understood.
- Dopamine system dysregulation is implicated in schizophrenia.
Purpose of the Study:
- To propose a framework for neurological development in schizophrenia using the Leonhard classification system.
- To explore biochemical hypotheses for differential treatment responses in schizophrenia subpopulations.
- To identify potential novel therapeutic targets for chronic schizophrenia.
Main Methods:
- Speculative analysis based on existing clinical observations and biochemical theories.
- Review of treatment responses to dopamine receptor blockers, beta-blockers, alpha-adrenergic agonists, and neuropeptides.
- Hypothesizing distinct biochemical profiles for schizophrenia subtypes, including catatonic schizophrenia.
Main Results:
- Nonsystematic schizophrenics may have altered dopamine beta-hydroxylase activity, explaining response to dopamine blockers.
- Acute schizophrenia stages may involve increased dopamine levels or receptor sensitivity, responsive to dopamine blockers.
- Catatonic schizophrenia may represent a biochemically distinct subtype, potentially benefiting from non-neuroleptic treatments.
Conclusions:
- The Leonhard classification system offers a promising framework for understanding schizophrenia.
- Different schizophrenia subpopulations likely require distinct pharmacological interventions.
- Emerging evidence suggests substances like propranolol, clordine, and cholecystokinin may treat specific patient groups, necessitating further research into differentiated drug activities.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
01:29Biological Causes of Schizophrenia
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
01:17Schizophrenia
Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those diagnosed.